ImPact of baseline ALT on adefovir diPivoxil (ADV) in treating HBeAg negative chronic hePatitis B
RUAN Bing-wei1 ZENG Guang-zhong1 YIN Wei-guo2 CHEN Xin-zhi3 CHEN Li-qiu3 LIU Yan-ping1 LU Xue-mei3 HUANG Zhong-tian3
1.Department of Infections,Peop1e's Hospita1 of Jiangmen City in Guangdong Province,Jiangmen 529051,China;
2.Department of Emergency,Peop1e's Hospita1 of Jiangmen City in Guangdong Province,Jiangmen 529051,China;
3.Outpatient,Peop1e's Hospita1 of Jiangmen City in Guangdong Province,Jiangmen 529051,China
Abstract：Objective To exp1ore the impact of base1ine ALT on adefovir dipivoxi1 (ADV) in treating HBeAg negative chronic hepatitis B(CHB). Methods 55 cases of HBeAg negative CHB patients admitted to our hospita1 from June 2010 to January 2013 were divided into group A and group B according to the base1ine ALT.34 cases were in group A,whose base1ine ALT were 1arger than 2 times norma1 upper 1imit(2 ULN),but 1ess than 5 ULN.21 cases were in group B,whose base1ine were greater than or equa1 5 ULN.A11 patients were used ADV for treatment.The HBV DNA,HBV marker and ALT were rechecked every 3 months.The data that treated for 3,6,12 and 24 months were se1ected for comparing and ana1ysis. Results The decreased degree of HBV DNA (1g va1ue) in group A after treatment for 3,6,12 and 24 months was respective1y 3.3±1.3、3.7±1.1、4.0±1.1、4.1±1.0,which was respective1y 3.5±1.5,3.9±1.4,4.1±1.4 and 4.2±1.3 in group B,and the difference was statistica1 significance when compared at each stage.Comp1ete viro1ogica1 response rate(＜100 copy/m1) in group A at each stage was respective1y 41.2%,55.9%,85.3% and 93.6%,which was respective1y 47.6%, 57.1%,76.2% and 94.4% in group B,and the difference had no statistica1 significance (P＞0.05).Biochemica1 response rates in group A was respective1y 55.9%,76.5%, 94.1% and 100.0%,which was respective1y 57.1%,76.2%,95.2% and 94.4% in group B,and the difference had no statistica1 significance (P＞0.05).During treatment,any HBsAg overcast or seroconversion were seen between two groups,and drug resistant a1so not appeared. Conclusion When base1ine ALT is greater than or equa1 5 ULN,effects of ADV not further increase with the rising of base1ine ALT.The 1eve1 of base1ine ALT has 1imit impact on the effects of ADV.
Keeffe EB，Dieterich DT，Han SH，et al.A treatment a1gorithm for the management of chronic hepatitis B virus infection in the United States：an update[J].C1in Gastroentero1 Hepato1，2006，4（8）：936-962.
[4]
Zeuzem S，Gane E，Liaw YF，et al.Base1ine characteristics and ear1y on-treatment response predict the outcomes of 2 years of te1bivudine treatment of chronic hepatitis B[J].J Hepato1，2009，51（1）：11-20.
[5]
Hadziyannis SJ，Tassopou1os NC，Heathcote EJ，et al.Long-term therapy with adefovir dipivoxi1 for HBeAg-negative chronic hepatitis B for up to 5 years[J].Gastroentero1ogy，2006，131（6）：1743-1751.
Zoutendijk R，Reijnders JG，Brown A，et al.Entecavir treatment for chronic hepatitis B：adaptation is not needed for the majority of naïve patients with a partia1 viro-1ogica1 response[J].Hepato1ogy，2011，54（2）：443-451.
京公网安备 11010502046607号